

CLAIMS

1. The use of at least one soluble HLA-G isoform for preparing a medicinal product intended for use in the treatment of blood circulation diseases.
2. The use as claimed in claim 1, characterized in that said diseases are selected from the group consisting of anemias and ischemias.
3. The use as claimed in claim 1 or claim 2, characterized in that said soluble HLA-G isoform is in the form of a composition also comprising at least one pharmaceutically acceptable vehicle.
4. The use as claimed in claim 3, characterized in that said composition is in liquid form.
5. The use as claimed in claim 3, characterized in that said composition is in solid form.
6. A method of detecting and, optionally, sorting cells of the erythrocyte and endothelial lines according to their state of differentiation, characterized in that it comprises:
  - a) bringing the biological sample to be tested into contact with antibodies directed against the following markers: soluble HLA-G isoform, CD71, CD34 and CD45, and
  - b) detecting and, optionally, sorting cells corresponding to various stages of differentiation of the erythrocyte or endothelial lines, according to their profile of expression of the markers defined in a).

7. The method as claimed in claim 6, characterized in that it comprises:
  - a) bringing the biological sample to be tested into contact with a panel of antibodies selected from the group consisting of antibodies directed against the following markers: soluble HLA-G isoform, CD71, CD34 and CD45, and
  - a') selecting the cells expressing the soluble HLA-G isoform, and
  - c) detecting the type of cell using the CD71 marker.
8. The method of detection as claimed in claim 6 or claim 7, characterized in that the biological sample is selected from the group consisting of a blood sample or a bone marrow sample.
9. The method of detection as claimed in any one of claims 6 to 8, characterized in that, prior to step a), the cells of said biological sample are permeabilized.